Multiple Sclerosis Journal - October 2017 - 1448

Multiple Sclerosis Journal 23(11)
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: N.D. is an
ECTRIMS fellow which is unrelated to the contents
of this publication; F.P. has received research support
from Biogen Idec; G.G. has received compensation
for participating in Advisory Boards in relation with
clinical trial design, trial steering committees, and
data and safety monitoring committees from Abbvie,
Bayer-Schering Healthcare, Biogen Idec, Eisai, Elan,
Fiveprime, Genzyme, Genentech, GSK, GW Pharma,
Ironwood, Merck-Serono, Novartis, Pfizer, Roche,
Sanofi-Aventis, Synthon BV, Teva, UCB Pharma and
Vertex Pharmaceuticals; S.G. has received personal
compensation for activities with Biogen, Genzyme,
Novartis and Teva, and research support from National
MS Society, Genzyme and Takeda.
Funding
The author(s) received no financial support for the
research, authorship and/or publication of this
article.

References
1. Lesko LJ and Atkinson AJ Jr. Use of biomarkers
and surrogate endpoints in drug development and
regulatory decision making: Criteria, validation,
strategies. Annu Rev Pharmacol Toxicol 2001; 41:
347-366.
2. Hill AB. The environment and disease: Association or
causation? Proc R Soc Med 1965; 58: 295-300.
3. Lee D-H, Steinacker P, Seubert S, et al. Role of glial
14-3-3 gamma protein in autoimmune demyelination.
J Neuroinflammation 2015; 12: 187.
4. Bartosik-Psujek H and Archelos JJ. Tau protein
and 14-3-3 are elevated in the cerebrospinal fluid of
patients with multiple sclerosis and correlate with
intrathecal synthesis of IgG. J Neurol 2004; 251(4):
414-420.
5. Colucci M, Roccatagliata L, Capello E, et al. The
14-3-3 protein in multiple sclerosis: A marker of
disease severity. Mult Scler 2004; 10(5): 477-481.
6. Kurnellas MP, Adams CM, Sobel RA, et al. Amyloid
fibrils composed of hexameric peptides attenuate
neuroinflammation. Sci Transl Med 2013; 5(179):
179ra42.
7. Boylan MT, Crockard AD, Duddy ME, et al.
Interferon-β1a administration results in a transient
increase of serum amyloid a protein and C-reactive
protein: Comparison with other markers of
inflammation. Immunol Lett 2001; 75(3): 191-197.

1448

8. Mori F, Rossi S, Sancesario G, et al. Cognitive
and cortical plasticity deficits correlate with
altered amyloid-β CSF levels in multiple sclerosis.
Neuropsychopharmacology 2011; 36(3): 559-568.
9. Bernardes D, Oliveira-Lima OC, Silva TV, et al.
Differential brain and spinal cord cytokine and BDNF
levels in experimental autoimmune encephalomyelitis
are modulated by prior and regular exercise.
J Neuroimmunol 2013; 264(1-2): 24-34.
10. Briken S, Rosenkranz SC, Keminer O, et al. Effects
of exercise on Irisin, BDNF and IL-6 serum levels
in patients with progressive multiple sclerosis.
J Neuroimmunol 2016; 299: 53-58.
11. Wens I, Keytsman C, Deckx N, et al. Brain derived
neurotrophic factor in multiple sclerosis: Effect
of 24 weeks endurance and resistance training.
Eur J Neurol 2016; 23(6): 1028-1035.
12. Tsakiri A, Ravanidis S, Lagoudaki R, et al.
Neuroprotective and anti-inflammatory mechanisms
are activated early in optic neuritis. Acta Neurol
Scand 2015; 131(5): 305-312.
13. Mashayekhi F, Salehi Z and Jamalzadeh HR.
Quantitative analysis of cerebrospinal fluid brain
derived neurotrophic factor in the patients with
multiple sclerosis. Acta Medica 2012; 55(2): 83-86.
14. Azoulay D, Vachapova V, Shihman B, et al. Lower
brain-derived neurotrophic factor in serum of
relapsing remitting MS: Reversal by glatiramer
acetate. J Neuroimmunol 2005; 167(1-2): 215-218.
15. Grygorowicz T, Wełniak-Kamińska M and
Strużyńska L. Early P2X7R-related astrogliosis in
autoimmune encephalomyelitis. Mol Cell Neurosci
2016; 74: 1-9.
16. Gnanapavan S, Grant D, Morant S, et al. Biomarker
report from the phase II lamotrigine trial in secondary
progressive MS - Neurofilament as a surrogate of
disease progression. PLoS ONE 2013; 8(8): e70019.
17. Axelsson M, Malmeström C, Nilsson S, et al. Glial
fibrillary acidic protein: A potential biomarker for
progression in multiple sclerosis. J Neurol 2011;
258(5): 882-888.
18. Martínez MAM, Olsson B, Bau L, et al. Glial and
neuronal markers in cerebrospinal fluid predict
progression in multiple sclerosis. Mult Scler 2015;
21(5): 550-561.
19. Petzold A, Eikelenboom MJ, Gveric D, et al. Markers
for different glial cell responses in multiple sclerosis:
Clinical and pathological correlations. Brain 2002;
125(Pt. 7): 1462-1473.
20. Rosengren LE, Lycke J and Andersen O. Glial
fibrillary acidic protein in CSF of multiple sclerosis
patients: Relation to neurological deficit. J Neurol Sci
1995; 133(1-2): 61-65.

journals.sagepub.com/home/msj

https://journals.sagepub.com/home/msj

Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017